EC
KROS icon

EJF Capital’s Keros Therapeutics KROS Stock Holding History

EJF Capital’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Hold
15,000
– – 0.11% 71
2026
Q1 		$166K Hold
15,000
– – 0.12% 68
2025
Q4 		$305K Buy
+15,000
New +$263K 0.17% 72

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

EJF Capital's KROS Position: Q2 2026 in Review

EJF Capital held its Keros Therapeutics (KROS) position steady in Q2 2026 at 15,000 shares worth $161K. The position accounts for 0.11% of the portfolio, ranked #71.

EJF Capital first reported a position in KROS in Q4 2025 and has held it in 3 quarters since. The position peaked at $305K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • EJF Capital held 15,000 shares of Keros Therapeutics worth $161K as of Q2 2026.
  • EJF Capital left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up 0.11% of EJF Capital's portfolio in Q2 2026, its #71 holding.
  • EJF Capital first reported a position in Keros Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • EJF Capital's Keros Therapeutics position peaked at $305K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on EJF Capital's 13F filing for Q2 2026, filed 13 Aug 2026.